Wedbush Reaffirms “Outperform” Rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Wedbush restated their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA – Free Report) in a research note issued to investors on Tuesday morning, RTT News reports. The firm currently has a $30.00 price objective on the stock, up from their prior price objective of $28.00. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ FY2027 earnings […]
More Stories
Targa Resources (NYSE:TRGP) Downgraded by US Capital Advisors to “Hold”
US Capital Advisors lowered shares of Targa Resources (NYSE:TRGP – Free Report) from a moderate buy rating to a hold...
Cencora, Inc. (NYSE:COR) Shares Acquired by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company raised its holdings in shares of Cencora, Inc. (NYSE:COR – Free Report) by 2.9% during...
Fmr LLC Acquires 1,741,835 Shares of Edison International (NYSE:EIX)
Fmr LLC increased its holdings in shares of Edison International (NYSE:EIX – Free Report) by 8.7% in the 3rd quarter,...
Principal Street Partners LLC Sells 5,115 Shares of Kirby Co. (NYSE:KEX)
Principal Street Partners LLC trimmed its holdings in Kirby Co. (NYSE:KEX – Free Report) by 74.3% in the 3rd quarter,...
Amdocs Limited (NASDAQ:DOX) Position Reduced by Fmr LLC
Fmr LLC cut its position in shares of Amdocs Limited (NASDAQ:DOX – Free Report) by 0.5% in the third quarter,...
Ventum Cap Mkts Has Negative View of CVE:AEP FY2025 Earnings
Atlas Engineered Products Ltd. (CVE:AEP – Free Report) – Ventum Cap Mkts decreased their FY2025 EPS estimates for shares of...